Independent Sales Contractor Agreement Template

Thursday, March 5th 2020. | Sample Templates

independent representative agreement calep midnightpig international sales representative agreement template 55 free invoice templates independent contractor agreement sale agreement form tario independent contractor agreement free independent contractor agreement template amendment to sales contract free 12 sample independent contractor agreement forms in beautysalon independent contractor agreement template – english a6fded95cb8c6aca1d9ad ec0a44 euepp
sale agreement form Independent Sales Contractor Agreement Template, source:pinterest.com
ontario independent contractor agreement rebqu
tario Independent Contractor Agreement Independent Sales Contractor Agreement Template, source:megadox.com
Sample Example & Format Templates Free Excel, Doc, PDF, xls free independent sales contractor agreement template independent sales contractor agreement template independent sales rep contract template salesperson agreement mission ly pdf free download independent contractor resume samples 72 property purchase offer letter template uk 5 sales contract templates – fine word templates consulting contract examples to use for your business manufacturing sales rep resume sample 9 free sample sales representative agreement templates bail bonds forms pdf elegant pretty sales rep contract independent contractor agreement for real estate salesperson licensing agreement form create a license in page 1 putdr
INTERNATIONAL SALES REPRESENTATIVE AGREEMENT TEMPLATE Independent Sales Contractor Agreement Template, source:docplayer.net
IC Business Invoice Template ituri
55 Free Invoice Templates Independent Sales Contractor Agreement Template, source:smartsheet.com
free independent contractor agreement template independent contractor agreement template free free independent contractor agreement template independent eawyr
Free Independent Contractor Agreement Template Independent Sales Contractor Agreement Template, source:75maingroup.com
Amendment20to20Sales20Contract 1 557x721 twaie
Amendment to Sales Contract Independent Sales Contractor Agreement Template, source:cissap.com
BestDox Independent Contractor Agreement sample pages v1 page 001 oaoea
Independent Contractor Agreement Independent Sales Contractor Agreement Template, source:bestdox.com

company earnings Agreements Saint-Leger, Randolf. "company earnings Agreements." Small business – Chron.com, http://smallbusiness.chron.com/company-earnings-agreements-47083.html. Accessed 26 March 2020. Saint-Leger, Randolf. (n.d.). company income Agreements. Small enterprise – Chron.com. Retrieved from http://smallbusiness.chron.com/corporate-earnings-agreements-47083.html Saint-Leger, Randolf. "company earnings Agreements" accessed March 26, 2020. http://smallbusiness.chron.com/corporate-sales-agreements-47083.html word: depending on which textual content editor you’re pasting into, you may must add the italics to the site identify. Biocept, Inc. (BIOC) CEO Michael Nall on this autumn 2019 consequences – earnings call Transcript Biocept, Inc. (NASDAQ:BIOC) this autumn 2019 results salary convention call March 25, 2020 4:30 PM ET company contributors Jody Cain – LHA, IR Michael Nall – President & CEO Tim Kennedy – SVP, Operations & CFO conference name members Michael Okunewitch – Maxim group Operator women and gentleman, thanks for standing-by way of. Welcome to the Biocept 2019 Fourth Quarter and entire yr fiscal consequences convention name. at the present, all members are in a hear-simplest mode. Following management’s prepared remarks, we can hold a query-and-reply session. [Operator Instructions]. As a reminder, this conference call is being recorded nowadays, March 25, 2020. i’d now want to turn the name over to Jody Cain. Please go forward, ma’am. Jody Cain here’s Jody Cain at LHA. thanks for collaborating in contemporary conference call. becoming a member of me from Biocept are Michael Nall, President and Chief govt Officer; and Tim Kennedy, Senior vice chairman of Operations and Chief fiscal Officer. all through this name, administration will be making a few ahead-looking statements inside the which means of the private Securities Litigation Reform Act of 1995. forward-searching statements encompass all statements that don’t seem to be historical information and generally can also be identified by way of phrases equivalent to expect, estimate, believes, could, expect, intend, might also, plans, abilities, predict, task, should still, will, would, or the negative of those terms. forward-searching statements involve regularly occurring and unknown risks, uncertainties and other components that could cause actual consequences, efficiency or achievements to be materially different from those statements, in addition to efficiency or achievements that are expressed or implied by means of the forward-looking statements. For details of these risks, please see the business’s SEC filings. The content of this call consists of time sensitive assistance it really is accurate only as of nowadays, March 25, 2020. except as required by way of legislation, Biocept disclaims any obligation to publicly update or revise any information to mirror events or instances that ensue after this call. Now, i might like to turn the name over to Michael Nall. Mike? Michael Nall thank you, Jody. And first rate afternoon, everyone. i am blissful to be reporting our impressive efficiency for the fourth quarter and entire yr with large growth in revenues and business samples. Revenues for the quarter reached a complete of $1.8 million, up 108% yr-over-12 months, and up 17% sequentially. business verify extent for the quarter multiplied forty six% over the prior year with regular repayment per patient up 34%. Importantly, our regular earnings per affected person pattern accelerated as we have been reporting on more tests per accession ordered by using referring physicians. We additionally benefited from operating efficiencies that decreased can charge of revenues per accession by using 12% versus the fourth quarter of 2018. Our results for this fall capped a superb year in which revenues grew with every passing quarter, attaining $5.5 million, up 70% over 2018. commercial revenues for the year were $5.1 million, a sixty eight% enhance, while commercial sample extent extended 35%. all through 2019 and into 2020, our group performed principally smartly throughout the board on our business priorities. Most primarily, we benefited from the center of attention on therapeutic segments where our goal Selector applied sciences and checking out platform can aid probably the most patients, namely prostate, breast, and lung cancers. Our hardworking income team’s efforts paid off with accession per earnings rep within the fourth quarter up forty three% from the prior yr. Our focal point on trying out for circulating tumor cells in prostate melanoma changed into a tremendous contributor to our revenue growth final year. remember that in early 2018, we recognized this as an area the place our liquid biopsy testing might add giant cost and we launched our product line with only 1 biomarker. Then, in early 2019, we improved our choices for urologists with extra prognostic and predictive biomarker look at various. because the 12 months improved, we gained momentum with new physicians ordering our functions for the primary time, more biomarkers ordered for pattern and extra reordering of assessments as some physicians begun the usage of our assay for monitoring sickness. we are focused on greater than 150 big urology group practices and the 2,400 urologists who are members of those group practices representing a big boom opportunity. Urologists are using our assessments for guys with intermediate grade prostate melanoma and are in view that whether or not they need to have greater aggressive medicine, akin to radical prostatectomy, or radiation remedy. These patients have a rising PSA and are undergoing watchful waiting with goal Selector testing picking out whether the prostate melanoma cells are circulating within the blood. a further area through which urologists are the usage of our trying out is the monitoring CTCs put up surgical procedure as a predictor of cancer prevalence. With few equipment purchasable to physicians to determine this, our checks tackle a major need. additionally in urology, we’re working with several enormous health professional practices and associations, as well as amassing facts in our own internal registry to compile and put up scientific facts to exhibit the utility of our liquid biopsy checking out platform in prostate melanoma. moreover, we’re carrying on with with enrollment in our cost efficient look at of patients with a rising PSA who have not been diagnosed with prostate melanoma. we will evaluate these results with tissue biopsy. If we demonstrate amazing concordance, we’ll then embark on a larger look at in this affected person population and what may ultimately be a new indication for Biocept. we are additionally leveraging our CTC platform and gaining acceptance in breast cancer. Physicians have begun to make use of our liquid biopsy checking out as a monitoring device for sufferers who’re originally proven poor for the biomarker HER2 which is generally treated with Herceptin or other anti-HER 2 healing procedures. devoid of settling on this biomarker of their tumor, a affected person will now not qualify for Herceptin therapy. published experiences indicate that approximately 20% of patients had been firstly established bad for HER2 will test positive for this biomarker and a subsequent biopsy. We consider that our target Selector CTC verify is among the most delicate blood assessments used to establish HER2 amplification. We’re working with Northwestern institution clinical core in Chicago and likely impartial investigators to reveal the scientific utility of our liquid biopsy assay for HER2 amplification. And we intend to post this statistics on this novel breast melanoma offering as quickly as subsequent 12 months. a different extremely good building ultimate 12 months changed into the launch of goal Selector NGS Lung and Breast, our first two multi-gene liquid biopsy panels. Biocept is the most effective industrial liquid biopsy provider of single-biomarker testing, tumor specific panel and CTC analysis. The subsequent generation sequencing or NGS panels run on the Thermo Fisher Scientific Ion Torrent NGS platform are being marketed to physicians and researchers for the detection and monitoring of actionable biomarkers linked to these tumors particular cancers. We predict to at ease Medicare compensation for these checks by Q3. We also won traction all through 2019 with our target Selector research use most effective or RUO kits and our CEE-sure specimen assortment tubes. Our RUO kits are used for the high sensitivity detection of EGFR biomarkers in lung melanoma and our blood assortment tubes enable for the transport assessments for molecular trying out during the realm devoid of refrigeration or special managing. This company is on a robust trajectory with consumers ordering basically $108,000 of those items in the fourth quarter, up from $5,000 within the first quarter of 2019. We plan to launch RUO package offerings for different assays sooner or later including the BRAF and KRAS biomarkers. We were delighted to receive CE IVD Marks for our blood assortment tube and sample assortment kits closing November. These certifications allowed us to market our assortment technologies within the eu and other geographies where the CE IVD Mark is recognized. Importantly, this is a different large milestone in our approach to develop the enterprise and our quest to manufacturer Biocept globally as a number one technology issuer in molecular diagnostics. among first rate developments to-date in 2020 we are now the primary and simplest country wide CLIA lab with a validated cerebrospinal fluid look at various for the detection of biomarkers. We all started work in this area in 2016 with Columbia university scientific center to consider the clinical utility of our goal Selector platform in sufferers with breast cancer and through our collaboration with a biopharma enterprise for lung cancer. Our trying out detects biomarkers current within the primary apprehensive gadget or CNS, which may turn up when tumor cells benefit entry to cerebrospinal fluid pathways, and regrow in far away websites in the spinal cord and mind resulting in neurological complication. Profiling biomarkers is essential to physicians picking the most fulfilling medication option for the 23% of breast melanoma sufferers and the 25% of lung cancer sufferers, who have metastases to the brain. whereas very early in our industrial launch, neuro-oncologists are captivated with our trying out. These neuro-oncology corporations in North the united states, Europe and Japan with mixed membership it truly is estimated to exceed 1,000 neuro-oncologists, making this a manageable doctor population through our revenue team. That spoke of, we estimate about 90,000 sufferers with breast or lung cancer reside long enough sufficiently to advance brain metastases, making this a promising and more profitable opportunity for Biocept. also this yr, we signed an settlement with a well-respected Northern California based mostly unbiased general practitioner association or IPA to provide our goal Selector trying out functions to physicians and sufferers in their community. today, i’m happy to announce, a 2d leading health equipment affiliated IPA, this one in Southern California is now beneath contract with Biocept. These are price-based mostly methods or capitated plans beneath which the healthcare suppliers pay the fixed quantity by using the firm to peer patients despite what number of treatment these sufferers received. We see these capitated plans which include IPAs, HMOs and ACOs as the style for healthcare in the u.s.. Our liquid biopsy checking out offers a solution through offering can charge efficient and excessive excellent care. These are our first predominant contracts with capitated plans and we expect to announce extra contracts as the yr progresses. We continue to present compelling statistics that further validates our know-how at scientific conferences and in a peer reviewed journals. previous this month, we announced the publication of up to now mentioned, yet incredibly compelling medical records in the Journal of scientific Pathology that further validates our target Selector qPCR assay, using patented switch Blocker technology to identify melanoma-related mutations in liquid biopsy sample. Our study examined 147 clinical assays for mutation commonly linked to cancer, achieved in sufferers with EGFR, BRAF and KRAS genes. each and every target Selector assay within the examine proven extraordinarily high accuracy, sensitivity and specificity in comparison to results obtained from tissue samples showing a ninety three% to ninety six% concordance to blinded tissue samples throughout all assay. In February, we introduced the merchandising of Cory Dunn, the Senior vice president of industrial Operations. Cory joined Biocept in late 2018 as vice president of advertising and marketing, having up to now held leadership positions within the diagnostics industry. we are particularly pleased with Cory’s performance in constructing our enterprise together with our focus in neurology. She has our earnings team united behind her and has seamlessly assumed leadership of our commercial operations. apart from our money steadiness at 2019 12 months-end, we now have raised combined web proceeds of approximately $17.5 million in 2020 via two back-to-back financings and warrant conversions. we are grateful to have achieved the financings with after market pricing and without a warrant. through reviewing our money position, that you would be able to see these dollars had been mandatory to fortify our steadiness sheet and assist our increase initiatives. We trust we now have sufficient money to execute on our boom approach in the course of the end of 2020. As a final subject, i might want to handle a controversy a lot of you’ve got raised concerning our position in checking out for coronavirus. Biocept, along with different diagnostic corporations, turned into listed in a contemporary article as having a possible to offer such testing. youngsters we certified to function this check in our CLIA-licensed high complexity lab and we’re evaluating different alternate options related to coronavirus trying out, we remain focused on assisting sufferers diagnosed with cancer. On March eleven, 2020, the area fitness corporation declared the unconventional strain of coronavirus had global pandemics and counseled containment and mitigation measures global. moreover, as we’re found in California, we are currently under a defend in place mandate and many of our consumers global are in a similar way impacted. As a healthcare provider, we’re allowed to remain open in compliance with the defend in place mandate, and continue to provide important tips for patients clinically determined with cancer. youngsters, the global outbreak of the COVID-19 coronavirus continues to all of a sudden evolve and the extent to which the COVID-19 coronavirus may additionally affect our business will rely upon future tendencies which can be highly uncertain and can’t be anticipated with self belief. amongst these uncertainties are the most desirable geographic unfold of the disorder, the period of the outbreak, trip restrictions and social distancing within the U.S. and other international locations, enterprise closures or enterprise disruption and the effectiveness of moves taken in the U.S. and other countries to include and treat the sickness. whereas we’re still receiving specimens from shoppers on a daily groundwork, we expect a potential slowdown in quantity as many sanatorium visits are being rescheduled and delayed. we’re continuing to vigilantly video display the situation with our simple focal point on the health and safety of our personnel, while offering leading edge features to our customers. And with that, i’ll flip the name over to Tim Kennedy to evaluate our economic outcomes. Tim? Tim Kennedy Thanks, Mike. And respectable afternoon, every person. As Mike outlined, for this autumn 2019, we said revenues of $1.eight million in comparison with $859,000 in q4 of 2018. This raise of 108% is due to greater accession volumes and an increase in reporting on greater exams per accession ordered via referring docs. Revenues have been up 17% sequentially from the $1.5 million suggested in Q3 2019. commercial compensation in accordance with historic combine and checks per accession bill increased in this fall to the $1,four hundred range, up from the $1,100 range in the prior yr length. The enhance was predominantly because of more reported biomarkers per accession. We proceed to launch new assays and enhance upon operational methods, leading to elevated trying out capabilities and health practitioner ordering. In this fall 2019, we bought 1,404 total accessions, up 35% versus 1,043 complete accessions in this fall 2018. commercial volume in q4 2019 changed into 1,159, up 46% in comparison with 795 in this autumn 2018. And as Mike mentioned, our business strategy is concentrated on surgeon specialties and certain market segments where we see colossal chance for our liquid biopsy trying out. Our execution on this method is using both boom and testing quantity. can charge of earnings for this fall 2019 as a percentage of revenues more suitable 122%. complete charge of revenues become $2.9 million, up 18% in comparison with the prior 12 months duration. again, this 18% boost in cost of profits is on a 108% boost in salary. charge of revenues on a per accession foundation become down 12% after declining 23% in the third quarter of 2019. As we continue to leverage the mounted components of charges with greater volume, while variable charge merits from advancements we are making to our approaches and workflow. In 2019, we implemented automation in our CLIA laboratories, which we consider led to extra leveraging of our fixed fees as we focus on our goal of superb gross margin. We count on being capable of deliver incremental laboratory potential at minimal expense to accommodate better extent. R&D costs were $1.2 million during the fourth quarter of 2019 in comparison with $1.three million right through the fourth quarter of 2018. The mild decline become because of lessen prices allotted to R&D associated with validations of latest assays and CLIA. G&A charges for this autumn 2019 were $1.9 million, a rise of $279,000 versus q4 2018 because of a re-category of client service and connected charges from earnings and advertising to G&A. youngsters, G&A prices as a percent of revenues more suitable 107% in this fall 2019 in comparison with a hundred ninety% in this fall 2018. revenue and advertising prices for this autumn 2019 had been $1.5 million compared with $1.4 million in this autumn 2018. The increase changed into basically attributable to commissions paid for higher pattern volume and salary. As a percentage of profits, earnings and marketing costs in this autumn 2019 narrowed to eighty three% versus 168% a yr in the past despite improved marketing expenses regarding the launch of recent exams. Our revenue drive productivity continues to improve as a result of the adjustments we’ve made with our industrial strategy, up 43% versus the prior yr duration. we’re pleased to document that with tightly controlling charges and becoming revenue, the net loss for the fourth of 2019 is down $279,000 or very nearly 5% versus the prior 12 months period. greater certainly, the internet loss brought on by normal shareholders for the fourth quarter of 2019 was $5.7 million or $0.20 per share on 29.1 million weighted normal shares surprising. This compares with a internet loss attributable to standard shareholders for the fourth quarter of 2018 of $6 million or $1.forty three per share on 4.2 million weighted commonplace shares awesome. And as a reminder, we conducted a 1-for-30 reverse stock cut up of our wonderful inventory in July 2018. Now turning to our results for the 12 months ended December 31, 2019. Revenues for 2019 expanded 70% to $5.5 million from $three.three million for 2018. The increase is because of effective execution from our commercial and operations team. From Q1 to this fall 2019, industrial revenue grew virtually 63% from $976,000 in Q1 to $1.6 million in q4. In 2019, we obtained four,425 industrial accessions, up 35% from 3,273 in 2018. As turned into the case for the fourth quarter, our full year boost displays our commercial strategy focused on definite health care provider specialties and specific market segments. cost of revenues for 2019 become $eleven million compared with $10.1 million for 2018. while cost of revenues accelerated ninety%, total accession volume bought elevated by means of 29%. R&D charges for 2019 were $four.7 million. G&A prices were $7 million and sales and marketing costs had been $5.9 million. The web loss for 2019 was $25.three million inclusive of a non-money fee of $2 million, which contains warrant inducement. The internet loss per share became $1.22 on 20.7 million weighted normal shares superb. This compares with a web loss for 2018 of $25.2 million. The net loss per share changed into $9.01 with about 2.8 million weighted normal shares stunning. cash and money equivalents have been $9.three million as of December 31, 2019, compared with $3.four million as of December 31, 2018. This comprises $25.7 million in web proceeds from fairness capital raises within the first and fourth quarters of 2019 and $four.9 million from the exercise of commonplace inventory warrants throughout 2019. additionally, as Mike referred to, throughout the first quarter of 2020, we raised net proceeds of about $14.6 million from two registered direct choices and $2.9 million from the exercised warrants. And with that, i will be able to now flip the call again over to Mike for a top level view of our commercial growth. Mike? Michael Nall thank you, Tim, and thank you on your leadership, consistently every day. we are expanding adoption of our patented proprietary liquid biopsy test with our huge providing of less invasive, least expensive solutions to aid physicians determine the top of the line medicine pathways for his or her patients with melanoma. we now have tested approximately 23,000 patient samples with our proprietary biomarker assays. These assays are in accordance with our differentiated platforms that leverage suggestions from both CTCs and ctDNA in blood and now cerebrospinal fluid. We proceed to generate clinical proof that helps the maximum sensitivity and specificity of our biomarker assay. in addition to drastically improving extent and revenues whereas managing fees, we are focused on expanding opportunities the place we will leverage the investment in our highbrow property, all with the aim to raise shareholder value. In closing, i might like to summarize our corporate priorities for 2020. These consist of: expanding market penetration into the rising liquid biopsy box with a focus on neuro-oncology, urology, breast and lung melanoma medicine segments; growing to be earnings of our goal Selector liquid biopsy kits, and our CEE-bound blood assortment tube; increasing market penetration of our goal Selector NGS lung and breast panels under our collaboration with Thermo Fisher and securing Medicare coverage for these panels; monetizing records from over 20,000 affected person samples using artificial intelligence or AI; getting into additional strategic commercial and know-how partnerships both world and home; signing new third-celebration health plan agreements, together with capitated plans and increasing our relationship with Blue move Blue shield; publishing medical case experiences and proposing facts at scientific conferences that extra validate our target Selector checking out; and launching further assays. Importantly, with the proceeds from our fresh fundraises, we’ve adequate capital to execute on these options. i would want to thank our complete team of Biocept for his or her very tough work and dedication as we strive to make 2020 one other particularly productive year. So with that overview, we’re now able to take questions. Operator? query-and-answer Session Operator [Operator Instructions]. Michael Nall Operator, while we’re expecting that first question, I’d want to once once again thank our investors for their confidence and their enthusiasm for our innovative providing. Operator Our first question comes from Jason McCarthy with Maxim neighborhood. Please go forward. Michael Okunewitch howdy, guys. this is Michael on for Jason. and i simply — first off, I just are looking to say congratulations on a pretty good quarter and basically a very good year standard. So, over 2019 you posted relatively incredible boom and it basically gave the impression of a turnaround story progressing from the low in 2018. And over time you definitely expanding your product choices with the NGS Panels, with the aid of focusing on prostate melanoma and empowered CTC, in addition to including industrial agreements. So, what I’d want to gauge from you is, what in fact have been the drivers for that growth in 2019? changed into it extra raise in the product offerings or expanding penetration of previously accessible items? And what do you predict to pressure boom going forward? Michael Nall So, thank you, Jason. i love that question. As we talked a bit bit in the prepared remarks, one of the most huge growth drivers in 2019 became our focus in urology. and that’s the reason an idea that Cory had led when she came visiting right here to Biocept and it turned into very a success for us. As we began to extend in urology for prostate cancer — and bear in mind, these are still folks diagnosed with cancer, there was a real need to be in a position to support these patients who had these intermediate grade cancers that they weren’t somewhat certain whether they desired to deal with more aggressively or now not. And so our check turned into an ideal healthy there and we have gotten decent adoption with our centered strategy. in addition, we now have seen boom in our scientific oncology phase too, primarily in breast cancer. in order that — I think these two pieces are basically what’s pushed lots of the increase. For 2020, what we’re in fact enthusiastic about is the neuro-oncology phase now with cerebrospinal fluid. That’s the market we need to ourselves at this aspect. And these individuals are very enthusiastic about our new providing in CSF because there may be really not a good alternative for that and they in fact want to be in a position to check the fluid this is closest to probably the most aggressive part of the tumor, which is a component it’s metastasized to the brain or principal fearful equipment. Michael Okunewitch thank you. and then truly on the urology facet, I’d like to see what is the aggressive abilities of Biocept’s liquid biopsies versus the different choice that make it principally appealing in this market? Michael Nall neatly, the massive differentiator — and that’s a superb question, is our focal point on circulating tumor cells, our capability to capture circulating tumor cells. Most different liquid biopsies — and folk who heard my shows earlier than are fairly lots focused on mobilephone free DNA. And we also study mobilephone free DNA. it’s respectable. it be a great source to get substances. but there you’re just trying to find the biomarkers to deal with affected person. in case you’re looking at the cells themselves, this is respectable counsel to know in itself. Are there cancer cells being shed out into the bloodstream? no longer each patient has that. And so in the event that they do not, those are doubtless first rate candidates to watch [wait]. if they do have CTCs being shed that cancer is probably greater aggressive, you are looking to treat it greater aggressive. And so it is how the physicians are the usage of it. and that is the reason the big differentiator for us in that area versus areas the place or not it’s simply in fact on the biomarkers only, like lung melanoma. Michael Okunewitch thanks. after which yet another from me and then i could hop lower back into queue. So in this fall, your can charge of goods went down on a per accession basis and sequentially was also especially flat on an absolute groundwork. So i might like to get somewhat more color on what are the components contributing to your extra efficient charge of goods? Michael Nall smartly, i go to let Tim provide you with lots of the detail there. i’d just say that, that changed into our focal point and is still a focus of the enterprise. we’ve introduced in lots of automation and that’s the reason below Tim’s management and that is the reason in fact paid off. but Tim, do you desire add a bit bit greater color to that? Tim Kennedy sure, I consider you hit the nail on the pinnacle there Mike and Jason, a very good remark there. As i mentioned in my organized remarks, we do expect to be in a position to continue to leverage the fastened components of can charge. And the manner we’re doing it really is citing extra automation like we did in 2019 — at the end of 2019 and we’ll proceed to deliver up automation moving ahead. And we expect that as we — to — to be able to accommodate extra extent growth, we trust that we’ll be in a position to accomplish that without adding a significant labor to our costs. So the variable charges associated with consumables, you will see that fee most likely move as our volume moves. but of path, as our extent grows, we can command larger and higher coupon codes from companies that we buy consumables from. so that can charge on a variable basis may still additionally go down. but Mike is completely correct, automation is what’s enabling us to basically scale and accommodate quantity increase with minimal can charge being added to charge of earnings. Operator [Operator Instructions]. The next question is from [John Quitta] with Scotiabank. Please go forward. Unidentified Analyst So my query, I failed to understand very neatly is, you are being worried in coronavirus checking out as a result of presently we now have worldwide emergency which Biocept has a very large lab also, so the physicians — we — and for every person presently in the us and worldwide. we would like to hear clearly, if in reality you have got the coronavirus look at various? second question, i want to understand — as a result of presently you may lose NASDAQ compliance very quickly since the inventory is buying and selling beneath $1. Are you reversing stock or you have the method of non-reversing stock below gaining the compliance? What do you say on these questions? otherwise, definitely I thank you very a lot and that i admire being in this convention name and i like Biocept. however I’d would want to hear obviously, so the aspects on both questions. thanks. Michael Nall thank you John for the question. it be a typical question and we frequently get buyers calling in to ask about coronavirus at this element. Of course it’s on the true of everybody’s mind all through the world. and i trust your sentiment there. As i discussed in my organized remarks, the enterprise nowadays has made no public statements about performing coronavirus testing other than what I shared nowadays and that we’ve excessive complexity molecular laboratory with the as it should be knowledgeable workforce and the mandatory certifications to be in a position to function such trying out. At this element, essentially the most that we’re sharing is that we’re evaluating diverse alternate options and we’ll have more suggestions possibly about that going ahead. So, aside from that, it truly is all that we will say at this point about that. so far as the inventory expense, sure, we’re commonplace with that. And NASDAQ does have numerous mechanisms to lengthen your runway with a view to tackle that and we’re evaluating the highest quality alternate options for the business. we’ve — are in respectable standing with NASDAQ, it’s important about Biocept. Tim and the team and our attorneys do an excellent job making certain we’re at all times in compliance there. And so we’ve an excellent relationship. So, at this factor, we shouldn’t have any public announcement about any plans for a reverse break up, however investors should recognize that we aren’t asleep on the wheel and that i’m very a great deal actively involved in that enviornment. Operator This concludes our question-and-answer session. i need to show the conference again over to Mike Nall for any closing remarks. Michael Nall smartly, thanks all very a lot. And so, on behalf of our Board of administrators and our hardworking group at Biocept, I are looking to as soon as once again thank each person for collaborating on trendy call and in your activity in our enterprise. we’re excited about our progress and seem ahead to presenting an replace on our subsequent conference name. we will report our first quarter 2020 economic effects in may additionally. thanks, every person, and have a fine day and please, please dwell fit and safe. Thanks. Operator The conference has now concluded. thank you for attending contemporary presentation. You might also now disconnect. how to Add Contract Work to LinkedIn Use your LinkedIn tagline to spotlight your strengths and competencies. Justin Sullivan/Getty photographs information/Getty images LinkedIn, a business social network, gives you with a wide array of equipment to latest your past and latest work guidance on the Profile web page of your account. despite the fact, one device that LinkedIn does not deliver is an obtrusive choice for including contract or self-employment work. since the Profile web page is extraordinarily flexible content-smart, including this counsel depends fully on the place you consider your contract tips greatest serves to spotlight your event and entice skills valued clientele. Profile Headline Your professional headline is the leading header to your profile that announces your existing title. LinkedIn recommends that unbiased contractors use "Self-Employed" with a profession title during this field — for example, "Self-Employed – Social Media manager." As different LinkedIn clients and placement guests see your headline first, and a few areas of LinkedIn demonstrate most effective your identify and this headline, an extra way you could use the headline is via inserting your work title and your region or a capture-phrase within the field and LinkedIn’s suggestion in the "Add position" box. for instance, a self-employed salesperson may use "unbiased sales professional in Chicago." in this box. A self-employed contractor could use "Contract chippie, able to support you make a apartment a house." abstract The "abstract" area of your LinkedIn profile is where you inform your expert story — your historical past, advantage, successes and enterprise desires. This area is also where you provide a abstract of the accomplishments and tasks that you simply’re most proud of and a short record of the advantage and qualities you present that you simply suppose benefit valued clientele. spotlight your contract experience because it pertains to your story. additionally, within the Specialties container, use keyword phrases that relate both to your career container and contracting. as an instance, use phrases like "contractor," "contract," "freelancer," "freelance" and "independent consultant" along with job varieties and potential. event The "adventure" enviornment is the place you destroy down your previous work with the aid of position. The "Add place" kind you utilize for this enviornment doesn’t have a field for self-employment. as a substitute, it has a "company name" container. Many clients do not know if they should still checklist each contract as a separate position with customer’s name during this box or use their company name and the names of shoppers within the "Description" field. As many companies emphasize that contractors aren’t personnel, many contractors have considerations about burning bridges if they use a consumer names. LinkedIn offers two innovations for tackling contract work within the "journey" enviornment — use a client’s identify or "Self-Employed" in the "enterprise identify" box. As there isn’t a set rule, you have to make the determination on the course to take. As for the "Title" field, state that you’re a contractor with key terms akin to "unbiased professional" or "Freelancer" and the exact title for the category of work you carried out. as an instance, a photo designer may use "unbiased expert – photo fashion designer." ultimate Consideration Contractors who’ve signed non-disclosure agreements (NDAs) or who have completed a assignment in a "ghost" means, during which a person else claimed credit score for the work as part of the contract agreement, have agreed no longer to divulge definite counsel. if you’ve signed an NDA, don’t checklist a company’s identify or specifics about your contracts on your LinkedIn profile, as doing so will make you seem unprofessional to those consumers. additionally, which you could face felony complications if a old NDA client discovers that you just’re publicly asserting this work. If the customer doesn’t intellect you record at least his enterprise identify, use it within the "Add place form company name" or "Description" fields and outline within the "Description" container that the place covered an NDA. These little details could make you seem greater knowledgeable. They display that you’ve got respected your shoppers, stored your agreements and have previous journey with NDAs. about the author primarily based in Southern Pennsylvania, Irene A. Blake has been writing on a wide range of issues for over a decade. Her work has looked in initiatives with the aid of The national network for Artist Placement, the-telephone-ebook restricted and GateHouse Media. She holds a Bachelor of Arts in English from Shippensburg college. photo credit Justin Sullivan/Getty photos information/Getty images bibliography-iconicon for annotation tool Cite this article select citation fashion MLA APA Chicago (B) A., Irene. "a way to Add Contract Work to LinkedIn." Small enterprise – Chron.com, http://smallbusiness.chron.com/add-contract-work-linkedin-38802.html. Accessed 26 March 2020. A., Irene. (n.d.). the way to Add Contract Work to LinkedIn. Small enterprise – Chron.com. Retrieved from http://smallbusiness.chron.com/add-contract-work-linkedin-38802.html A., Irene. "a way to Add Contract Work to LinkedIn" accessed March 26, 2020. http://smallbusiness.chron.com/add-contract-work-linkedin-38802.html replica citation notice: reckoning on which text editor you’re pasting into, you might should add the italics to the website identify..
contract sales representative agreement distribution agreement template 9 free sample sales representative agreement templates sales mission agreement form generate and a professional seo contract bonsai solar project origination lead generator agreement 20 relationship contract templates & relationship agreements work for hire agreement approveme free contract templates download 1099 forms for independent contractors unique independent sales rep contract template hire a recruiter independent sales representative contract template

independent sales job description, independent contractor sales representative agreement, independent sales agents canada, independent sales representative agreement california, independent sales rep agreement sample, independent jewelry sales panies, independent sales agent contract template, independent sales consultant, best independent sales jobs, independent sales rep panies,

tags: , , ,